Laboratorios ASPEN incorporates Uveren® (Macitentan) into its Pulmonology Division, offering a new therapeutic alternative for patients with complex respiratory conditions.
This treatment is indicated for the long-term management of pulmonary arterial hypertension (PAH), a rare and highly complex disease, helping to improve the condition and quality of life of those who suffer from it.
Available presentation:
- Coated tablets of 10 mg.
With Uveren®, we reinforce our commitment to constantly develop and provide innovative medicines for diseases that require a specialized and careful approach.